Yaride Pérez-Pacheco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yaride Pérez-Pacheco has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bartosz Tylkowski
Eurecat, Centre Tecnològic de Catalunya, Chemical Technologies Unit, Marcel·lí Domingo 2, 43007 Tarragona, Spain
4 shared publications Miquel Sisteré
Sisvilab, Prat de la Riba 63,1,2, Lleida 25004, Spain
3 shared publications- Ricard Garcia-Valls
Department of Chemical Engineering, Universitat Rovira i Virgili, Av. Països Catalans 26, Campus Sescelades, 43007 Tarragona, Spain
2 shared publications Ricard García-Valls
2 shared publications- Ricard García-Valls
Univ Rovira i Virgili, Chem Engn Dept, Av Paisos Catalans 18, Tarragona 43073, Spain
2 shared publications Tiziano Alimandi
Tuscia Univ, Via Santa Maria Gradi 4, I-01100 Viterbo, VT, Italy
2 shared publications
Latest Publications
- 2 March 2026
- Published by Grupo Pacifico
Development of Spray Dried Chitosan-TPP Microcapsules for Drug Delivery
- 2 March 2026
- Published by Grupo Pacifico
Development of Spray Dried Chitosan-TPP Microcapsules for Drug Delivery
- Open Access
- 30 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1387
Emerging Nanomedicine Strategies for Chronic Disease Management Based on Chitosan
Chronic diseases such as cancer, cardiovascular disorders, neurodegenerative conditions, chronic respiratory diseases, autoimmune disorders, chronic kidney disease, persistent infectious diseases, diabetes, and ocular inflammation remain leading causes of morbidity and mortality worldwide. Their complex pathophysiologies and the limitations of conventional therapies underscore the urgent need for advanced drug delivery platforms that enhance therapeutic efficacy while minimizing off-target effects and systemic toxicity leading to adverse reactions. Nanomedicine has emerged as a transformative approach, with chitosan-based nanocarriers offering advantages due to their biocompatibility, biodegradability, mucoadhesive properties, and ability to be physic-chemically modified. These nanocarriers improve solubility, stability, bioavailability, and the therapeutic index of drugs, while enabling controlled release, targeted delivery, and immune modulation. This review highlights recent advances in chitosan-based nanomedicine for the management of chronic disease. We discuss methods of synthesis such as ionic gelation and electrospray, functionalization approaches, and immunomodulatory roles that expand therapeutic potential. The evidence emphasizes that chitosan nanocarriers are a versatile, safe, and effective platform which can be used to improve clinical results, reduce adverse effects, and advance the science of personalized medicine.
- 30 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1387
Open AccessEmerging Nanomedicine Strategies for Chronic Disease Management Based on Chitosan
Chronic diseases such as cancer, cardiovascular disorders, neurodegenerative conditions, chronic respiratory diseases, autoimmune disorders, chronic kidney disease, persistent infectious diseases, diabetes, and ocular inflammation remain leading causes of morbidity and mortality worldwide. Their complex pathophysiologies and the limitations of conventional therapies underscore the urgent need for advanced drug delivery platforms that enhance therapeutic efficacy while minimizing off-target effects and systemic toxicity leading to adverse reactions. Nanomedicine has emerged as a transformative approach, with chitosan-based nanocarriers offering advantages due to their biocompatibility, biodegradability, mucoadhesive properties, and ability to be physic-chemically modified. These nanocarriers improve solubility, stability, bioavailability, and the therapeutic index of drugs, while enabling controlled release, targeted delivery, and immune modulation. This review highlights recent advances in chitosan-based nanomedicine for the management of chronic disease. We discuss methods of synthesis such as ionic gelation and electrospray, functionalization approaches, and immunomodulatory roles that expand therapeutic potential. The evidence emphasizes that chitosan nanocarriers are a versatile, safe, and effective platform which can be used to improve clinical results, reduce adverse effects, and advance the science of personalized medicine.
- Open Access
Chitosan Micro/Nanocapsules in Action: Linking Design, Production, and Therapeutic Application
PH sensitivity of chitosan allows for precise phase transitions in acidic environments, controlling swelling and shrinking, making chitosan suitable for drug delivery systems. pH transitions are modulated by the presence of cross-linkers by the functionalization of the chitosan chain. This review relays a summary of chitosan functionalization and tailoring to optimize drug release. The potential to customize chitosan for different environments and therapeutic uses introduces opportunities for drug encapsulation and release. The focus on improving drug encapsulation and sustained release in specific tissues is an advanced interpretation, reflecting the evolving role of chitosan in achieving targeted and more efficient therapeutic outcomes. This review describes strategies to improve solubility and stability and ensure the controlled release of encapsulated drugs. The discussion on optimizing factors like cross-linking density, particle size, and pH for controlled drug release introduces a deeper understanding of how to achieve specific therapeutic effects. These strategies represent a refined approach to designing chitosan-based systems, pushing the boundaries of sustained release technologies and offering new avenues for precise drug delivery profiles.
Open AccessChitosan Micro/Nanocapsules in Action: Linking Design, Production, and Therapeutic Application
PH sensitivity of chitosan allows for precise phase transitions in acidic environments, controlling swelling and shrinking, making chitosan suitable for drug delivery systems. pH transitions are modulated by the presence of cross-linkers by the functionalization of the chitosan chain. This review relays a summary of chitosan functionalization and tailoring to optimize drug release. The potential to customize chitosan for different environments and therapeutic uses introduces opportunities for drug encapsulation and release. The focus on improving drug encapsulation and sustained release in specific tissues is an advanced interpretation, reflecting the evolving role of chitosan in achieving targeted and more efficient therapeutic outcomes. This review describes strategies to improve solubility and stability and ensure the controlled release of encapsulated drugs. The discussion on optimizing factors like cross-linking density, particle size, and pH for controlled drug release introduces a deeper understanding of how to achieve specific therapeutic effects. These strategies represent a refined approach to designing chitosan-based systems, pushing the boundaries of sustained release technologies and offering new avenues for precise drug delivery profiles.
- 28 February 2024
- Published by Institut Quimic de Sarria in Afinidad. Journal of Chemical Engineering Theoretical and Applied Chemistry
- Vol. 81 (601) , 33-43
Chitosan-TPP microcapsules for controlled drug release
- 28 February 2024
- Published by Institut Quimic de Sarria in Afinidad. Journal of Chemical Engineering Theoretical and Applied Chemistry
- Vol. 81 (601) , 33-43
Chitosan-TPP microcapsules for controlled drug release
- 1 February 2023
- Published by Grupo Pacifico
Chitosan-TPP microcapsules for controlled drug release
- 29 January 2020
- Published by Grupo Pacifico
Capsules of Chitosan a tailor drug delivery system with controlled release for specific organs
- 29 January 2020
- Published by Grupo Pacifico
Capsules of Chitosan a tailor drug delivery system with controlled release for specific organs
- Open Access
- 24 January 2017
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 786 (1) , 012043
Platinum leaching from automotive catalytic converters with aqua regia
Bimetallic Pd-Au nanocluster arrays grown on nanostructured
- 24 January 2017
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 786 (1) , 012043
Open AccessPlatinum leaching from automotive catalytic converters with aqua regia
Bimetallic Pd-Au nanocluster arrays grown on nanostructured